Journal of the International Society of Sports Nutrition · 2023 · 20 citations · 35 references
MedicinePharmacologySports MedicineClinical PharmacologyExercise PhysiologySports NutritionCannabinoid PharmacologyExercise TherapyMuscle StrengtheningRecovery StrategiesAdverse Effects Of CannabinoidsAmino AcidsBranched-chain Amino AcidsPlacebo ComparatorsPlacebo Effects In SupplementationRecovery BeveragesTherapeutic Cannabinoid Use
BACKGROUND: Cannabinoid-containing products are marketed to athletes as promoting recovery, in spite of a lack of data on their safety and effects. This randomized, double-blind, placebo-controlled, repeated-dose pilot study tested the safety, tolerability, and preliminary effects on recovery of a formulation containing cannabidiol (CBD; 35 mg), cannabigerol (CBG; 50 mg), beta caryophyllene (BCP; 25 mg), branched-chain amino acids (BCAAs; 3.8 g), and magnesium citrate (420 mg). METHODS: = 40) underwent an experimental induction of delayed onset muscle soreness (DOMS) and completed follow-up visits 24-, 48-, and 72-hours post-DOMS. Participants were randomized to active or placebo formulation, and consumed the formulation twice per day for 3.5 days. RESULTS: There was one adverse event (AE) in the active group (diarrhea) and two AEs in placebo (dry mouth; eye rash/swollen eye). There was 100% self-reported compliance with formulation consumption across the two groups. For the primary outcome of interest, the estimate of effect for ratings of average soreness/discomfort 72 hours post-DOMS between active and placebo groups was -1.33 (85% confidence interval = -2.55, -0.10), suggesting moderate evidence of a treatment difference. The estimate of effect for the outcome of ratings of interference of soreness, discomfort, or stiffness on daily activities at work or home 48 hours post-DOMS was -1.82 (95% confidence interval = -3.64, -0.01), indicating a treatment difference of potential clinical importance. There was no significant effect between active and placebo groups on objective measures of recovery, sleep quality, or mood disturbance. CONCLUSIONS: The tested formulation reduced interference of DOMS on daily activities, demonstrating its improvement on a functional aspect of recovery.
35
Beta-caryophyllene is a dietary cannabinoid
Jürg Gertsch, Marco Leonti, Stefan Raduner et al. · Proceedings of the National Academy of Sciences · 2008 · 879 citations · Full text
Medicine, Botany, Pharmacology +17
Robert Z. Tashjian, Julia Deloach, Christina A. Porucznik et al. · Journal of Shoulder and Elbow Surgery · 2009 · 661 citations
Lesley Taylor, Barry E. Gidal, Graham Blakey et al. · CNS Drugs · 2018 · 464 citations · Full text